As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.


Table S1. Interference screening results for the 60 interference-free peptides targeting 27 cancer-related plasma proteins analysed on Agilent's standard-flow LC-MRM/MS platform. Data are displayed as average relative ratios between SIS in buffer, SIS in plasma, and NAT in plasma for 3 transitions per peptide (%CVs indicated in paranthesis). Each peptide's transitions are ranked according to their average relative ratios, variability, and NAT vs. SIS peak symmetry comparisons.

Table S2. Optimized MRM parameters for 60 peptides representing 27 cancer-related plasma proteins (masses and m/z values listed are for the natural (NAT) peptide forms).

Table S3. Analytical reproducibility, linearity, sensitivity, plasma protein concentration, and quantitation accuracy for a 57-peptide panel (representing 27 plasma proteins) obtained from per-peptide calibration curves (n = 5 for each of the 8 concentration levels)

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.